Indee Labs is enabling more effective engineered cell therapy with microfluidics
We believe microfluidics can be used to integrate the entire engineered cell therapy manufacturing process into a simple microfluidic consumable with a small form factor. Our peer-reviewed data shows our core technology results in higher quality engineered cells that will improve patient outcomes. We are always looking for exceptional people who are interested in joining the team.
Indee Labs is a biotechnology startup backed by SOSV, Y Combinator, Social Capital and Founders Fund. The team at Indee Labs develops and markets Hydropore for more effective engineered cell therapies.
Indee Lab’s non-viral delivery platform, Hydropore, is a robust solution that overcomes the limitations and costs of electroporation, viral transduction, and other non-viral transfection methods. Hydropore is being developed in collaboration with 3 of the top 10 pharmaceutical companies, various biotechs and leading research institutions including UC San Francisco, Stanford, Medical University of South Carolina, the National Cancer Institute and the National Institute of Allergy and Infectious Disease among others.